Search clinical trials for: Gemcitabine Cisplatin

Total 5710 results

Samsung Medical Center

Withdrawn

Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company

Completed

Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas

Biliary Tract Carcinoma

Korea, Republic of
The Netherlands Cancer Institute
Karolinska Institutet; UMC Utrecht; Maastricht Radiation Oncology; The Christie... and other collaborators

Active, not recruiting

Adaptive Radiation Treatment for Head and Neck Cancer (ARTFORCE)

Head and Neck Cancer

Spain, Netherlands, Sweden, France, United Kingdom
Nanfang Hospital, Southern Medical University

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Chengjun Sui,MD

Not yet recruiting

Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Organoids
Eli Lilly and Company

Completed

Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer

Non-Small Cell Lung Cancer

China
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary

Carcinoma

France
Eli Lilly and Company

Completed

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Carcinoma, Non-Small-Cell Lung

Russian Federation
Albert Einstein College of Medicine
Shanghai Proton and Heavy Ion Center

Completed

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Cancer | Pancreatic Cancer

United States, China
Sun Yat-sen University
Chongqing University Cancer Hospital; Jiangxi Provincial Cancer Hospital; Shenzhen... and other collaborators

Recruiting

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Cancer

United States, Canada
The University of Texas Health Science Center,...

Unknown

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (FR-WB-TT/che)

Small Cell Lung Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Cancer

United States
Radboud University Medical Center

Completed

Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

Melanoma

Netherlands
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

China, Hong Kong, Taiwan, Philippines, Thailand, Korea, Republic of, Indonesia
National Cancer Institute, Naples
Gruppo Oncologico Italia Meridionale; Gruppo Italiano per lo studio dei Carcinomi... and other collaborators

Terminated

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients (CAPPA-2)

Non-Small Cell Lung Cancer

Italy
Eli Lilly and Company

Completed

Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes

Metastatic Breast Cancer

Saudi Arabia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer

China
Pancreatic Cancer Research Team
Celgene

Withdrawn

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Resectable Pancreatic Cancer
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Bladder Cancer

Bladder Cancer

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Italy
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
University Health Network, Toronto
Bladder Cancer Canada

Recruiting

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (NAUTICAL)

Bladder Cancer | Bladder Urothelial Carcinoma

Canada
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
University Health Network, Toronto

Active, not recruiting

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Gallbladder Carcinoma | Biliary Tract Carcinoma

Canada
Hope Cancer Institute, Inc.

Unknown

Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck

Head and Neck Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Canada
Fudan University

Completed

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Metastatic Breast Cancer

China
Hoffmann-La Roche

Withdrawn

A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease

Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute, Naples

Completed

MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer
Govind Ballabh Pant Institute of Postgraduate Medical...

Completed

Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma

Gallbladder Cancer

India
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
Hospital do Coracao
University of Sao Paulo

Not yet recruiting

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer (AddChemo)

Cervical Cancer | Cervix Cancer | Cervix Neoplasm

Brazil
Curis, Inc.

Completed

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Head and Neck Cancer

United States
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
Eli Lilly and Company

Completed

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Breast Cancer

China, India, Turkey, Korea, Republic of, Brazil, Mexico
IRCCS San Raffaele

Completed

Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer (PACT-7)

Pancreatic Cancer

Italy
AstraZeneca

Completed

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer (SELECT-3)

Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV

United Kingdom
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Sanofi

Completed

Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

Italy
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Eli Lilly and Company

Completed

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

Non-Small Cell Lung Cancer

Belgium, Bosnia and Herzegovina, Bulgaria, Egypt, Estonia, Germany, Hungary, Italy, Lithuania, Poland, Romania, Saudi Arabia, Slovakia, Sweden, Taiwan
Eli Lilly and Company

Completed

Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer

Bladder Cancer

Poland
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
Eli Lilly and Company

Completed

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Netherlands, Spain, United States, Canada, Israel, Germany
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States, Australia, Georgia

Search clinical trials for: Gemcitabine Cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations